logo
Plus   Neg
Share
Email

Gilead Announces NDA Submission For Filgotinib In Japan - Quick Facts

Gilead Sciences, Inc. (GILD) has submitted a New Drug Application for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis, to the Japanese Ministry of Health, Labor and Welfare. The NDA is supported by data from the Phase 3 FINCH clinical trial program.

"This new drug application is an important milestone as we continue to expand Gilead's presence in Japan to now also include inflammation," said Luc Hermans, President and Representative Director, Gilead Sciences, K.K.

Filgotinib is an investigational agent and is not approved anywhere globally.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Retail Federation or NRF said that conflicting economic data amid a resurgence in coronavirus cases has made it difficult to predict how steadily the U.S. economic recovery will continue. NRF Chief Economist Jack Kleinhenz noted that based on quarterly and monthly data, the U.S. economic recovery is continuing despite the elevated COVID-19 cases. Ford Motor Company (F) announced that Jim Hackett plans to retire as President and CEO. He will continue as a special advisor to the company through March of 2021. The company has named Jim Farley as new president and CEO. He will join the board of directors, effective Oct. 1. Farley joined Ford in... Google parent Alphabet Inc. has issued $5.75 billion in sustainability bonds, becoming the largest green or sustainability bonds issued by a company until now. This is part of a $10 billion debt offering. Alphabet said the proceeds will be used to fund projects that are environmentally or socially responsible.
Follow RTT